Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc (Nasdaq: RPRX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its royalty-based business model, capital structure and portfolio performance. As a company incorporated in England and Wales with Class A ordinary shares listed on The Nasdaq Stock Market LLC under the symbol RPRX, its SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with registration statements and indenture-related documents.
In its filings, Royalty Pharma explains how it acquires and manages royalty interests on biopharmaceutical products and defines key metrics such as Portfolio Receipts, royalty receipts, milestones and other contractual receipts. The company also discloses non-GAAP liquidity measures, including Adjusted EBITDA, ROIC Adjusted EBITDA, Portfolio Cash Flow and ROIE Portfolio Cash Flow, and reconciles these to net cash provided by operating activities. Debt-related filings describe senior unsecured notes issued under an indenture among Royalty Pharma plc, Royalty Pharma Holdings Ltd, Royalty Pharma Manager, LLC and Wilmington Trust, National Association, as trustee, including coupon rates, maturities, guarantees and covenant terms.
Form 8-K current reports highlight material events such as quarterly earnings releases, debt offerings, changes in directors and other significant corporate developments. These filings can be used to track Royalty Pharma’s capital deployment into new royalty transactions, updates to its share repurchase program, dividend decisions and other actions affecting shareholders.
On Stock Titan’s SEC filings page for RPRX, users can access Royalty Pharma’s latest 10-K, 10-Q and 8-K filings as they are posted to EDGAR. AI-powered summaries help explain complex sections, such as the description of Portfolio Receipts, non-GAAP liquidity measures, and indenture provisions for senior notes, allowing readers to quickly understand the implications of lengthy documents. The page also surfaces Form 4 insider transaction reports, so users can review trading activity by directors and officers alongside the company’s broader disclosure record.
Royalty Pharma plc reported higher first-quarter 2026 results, driven by growth in royalty income and strong cash generation. Total income and other revenues reached $630.6 million, up from $568.2 million a year earlier, and net income attributable to Royalty Pharma plc rose to $294.7 million from $239.3 million.
Basic and diluted earnings per Class A share were $0.67, compared with $0.55 in 2025. Operating cash flow was robust at $718.2 million, while the company recorded a $69.4 million non-cash impairment on its Tazverik royalty and recognized $122.3 million of share-based compensation following its 2025 internalization. Cash stood at $586.4 million and total debt principal at $9.18 billion as of March 31, 2026.
Royalty Pharma plc reported strong first-quarter 2026 results, with double-digit growth and higher full-year guidance. Portfolio Receipts rose 10% to $925 million, while Royalty Receipts grew 13% to $887 million, driven mainly by Tremfya, Voranigo and Evrysdi. Net cash provided by operating activities increased 20% to $718 million.
Adjusted EBITDA climbed 21% to $889 million and Portfolio Cash Flow rose 18% to $722 million, highlighting robust cash generation. The company raised 2026 Portfolio Receipts guidance to $3,325 million–$3,450 million, implying expected Royalty Receipts growth of 4%–8%. Royalty Pharma also executed $528 million of capital deployment, including three royalty acquisitions with up to $1.25 billion in announced value, paid a quarterly dividend of $0.235 per share and repurchased about 1.1 million shares.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported open-market sales of a total of 34,791 Class A Ordinary Shares on April 28, 2026. The shares were sold at a weighted average price of $49.7784 per share through entities TPC RP EPA1 LLC and TPC RP 2021, LLC, under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. Following the transactions, TPC RP EPA1 LLC held 40,136 Class A Ordinary Shares, while TPC RP 2021, LLC held none, and the filing also lists additional direct and IRA-related holdings for Coyne and his spouse.
RPRX affiliate(s) reported proposed and recent sales of Common Stock via Form 144. The notice lists multiple dispositions by entities including TPC RP EPA1 LLC and TPC RP 2021 LLC, showing individual sale dates, share counts (examples: 1,875 and 32,916), and corresponding proceeds.
Royalty Pharma plc highlights positive Phase 3 results from partner Revolution Medicines’ RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. The study met all primary and key secondary endpoints, including progression-free and overall survival, and Revolution Medicines plans to submit the data to global regulators, including a future U.S. FDA New Drug Application.
These results activate the second $250 million tranche under a previously announced $2 billion funding deal between the companies, bringing Royalty Pharma’s funding to $500 million so far. Royalty Pharma is now entitled to tiered royalties of 4.55% on daraxonrasib (and certain zoldonrasib sales), with potential step-ups to as high as 7.80% on lower sales tiers if Revolution Medicines draws the remaining synthetic royalty funding, alongside access to a senior secured term loan facility of up to $750 million linked to FDA approval and future sales milestones.
Royalty Pharma plc is asking shareholders to vote at its 2026 Annual General Meeting on June 4, 2026 in New York. Items include electing nine directors, advisory votes on U.S. and U.K. executive pay, auditor ratifications, authority to repurchase Class A shares, and approvals to allot shares with and without pre-emption rights.
The company highlights 2025 performance with $3.3BN in portfolio receipts, $3.0BN in adjusted EBITDA, $2.7BN in portfolio cash flow, and $4.7BN in announced transaction value. It returned over $1.7BN to shareholders, including more than $1.2BN of buybacks, while deploying $2.6BN into royalty acquisitions.
Royalty Pharma completed internalization of its external manager, emphasizing stronger board oversight of compensation and succession. The largely independent, skills-diverse board—led by Chairman and CEO Pablo Legorreta and Lead Independent Director Ted Love—stresses pay-for-performance, robust share ownership guidelines, risk oversight, and corporate responsibility initiatives around responsible investment, human capital, and sustainability.
Royalty Pharma plc EVP & CFO Terrance P. Coyne, through affiliated entities, reported planned open-market sales of Class A Ordinary Shares. On April 1, 2026, TPC RP EPA1 LLC sold 1,875 shares and TPC RP 2021, LLC sold 32,916 shares at a weighted average price of $48.3318 per share, all under a Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, TPC RP EPA1 LLC held 42,011 shares and TPC RP 2021, LLC held 32,916 shares. Additional holdings reported include 24,170 shares in a spouse’s IRA, 23,270 shares in an IRA, 1,500 shares held directly, and 1,450 shares held by a spouse, indicating that the transactions represent a partial reduction of a larger overall position.
TPC RP EPA1 LLC and TPC RP 2021 LLC reported multiple sales of Common Stock under Form 144. The filings list numerous dispositions between 01/02/2026 and 03/23/2026, including large line items such as 108,759 shares sold on 02/03/2026 and 69,665 shares sold on 02/02/2026. The entries show per-transaction share amounts and gross proceeds for each sale.
Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Bonnie L. Bassler received an equity grant of 815 Class A Ordinary Shares. The award was made on a grant/award basis at a reference price of $45.977 per share and was issued under the company’s 2020 Independent Director Equity Incentive Plan in lieu of a $37,500 quarterly retainer payment. Following this grant, Bassler directly holds 73,947 Class A Ordinary Shares.